Northstar Select®
Unmatched sensitivity for more treatment opportunities.
Reduction in false negative results1
More pathogenic CNAs detected
Northstar Select® is the most sensitive ctDNA liquid biopsy that uses QCT™ technology to guide therapy selection by detecting actionable alterations, even in low tumor fraction samples.
A purpose-built
liquid biopsy.
Northstar Select® uncovers treatment opportunities others miss — focused on the genes that matter most for therapy selection.
High (MSI-H) status
Low VAF alterations can be found even in traditionally high-shedding tumors1.
Northstar Select achieves a 2 to 5x lower limit of detection than other liquid biopsies2.
Northstar Select uncovered 50%+ more pathogenic alterations1.
Download Helpful Resources
FAQ for Northstar Select®
Data generated on the 84-gene Northstar Panel. Bower et al. J Liq Biopsy, 2025. Head-to-head improvement % determined when compared to the comparator products in the aggregate. Actual percentages may vary depending on the individual comparator liquid biopsy test.
LOD 95% (limit of detection 95%) is defined as the lowest concentration of an analyte in a sample that can be consistently detected with ≥95% probability. Comparator assays have a LOD 95% that ranges from 0.20% -0.40%.
More answers start here.
